Transition Structures Between Unbound and Bound SARS-CoV-2 Spike Protein to Human ACE2: Potential Targets for Drug Design

01 June 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

The recent outbreak of COVID-19 caused by SARS-CoV-2 led to a race in finding a cure. Different drug targets were recognized, but in most cases the main target has been identified in the virus spike protein because it is crucial for the virus to gain entry into human cells. The virus spike protein undergoes large dynamic changes in order to bind to the entry point in human cells, which is a surface protein known as Angiotensin-Converting Enzyme 2 (ACE2). The spike – ACE2 interaction represents the major target for vaccines and antiviral drugs. Incidentally, all intermediate structures in the folding pathways could become potential drug targets. This study reports the simulation of the transition pathway of the spike protein and includes its animation that can help also non-experts to visually understand how the infection starts. The simulation of the spike protein's transition pathway has been done by using the NMSim software, which makes use of a three-step protocol including Coarse Grain, Normal Mode Analysis, and Elastic Network Model methods, providing realistic intermediates at a reasonable simulation time.

Keywords

COVID-19
SARS-CoV-2
Spike Protein Motion

Supplementary materials

Title
Description
Actions
Title
Supplementary materials
Description
Actions
Title
MovieS1
Description
Actions
Title
MovieS2
Description
Actions
Title
PathRCNMA120
Description
Actions
Title
Spike+ACE2-DownState
Description
Actions
Title
Spike+ACE2-UpState
Description
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.